By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Addex Therapeutics 

12, Chemin Des Aulx
1228 Plan-les-Ouates
Geneva      Switzerland
Phone: 41-22-884-1555 Fax: 41-22-884-1556


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Addex Therapeutics (ADXN.SW) Dipraglurant Dosed In First Subject In Receptor Occupancy Study In Collaboration With Johns Hopkins University And With Funding From The Michael J. Fox Foundation 7/22/2015 10:50:44 AM
Addex Therapeutics (ADXN.SW) Shareholders Appoint Raymond Hill And Tim Dyer To The Board Of Directors And Approve All Board Proposals At Annual General Meeting 6/12/2015 8:54:16 AM
Addex Therapeutics (ADXN.SW) Identifies New Potential Use Of mGlu7 Receptor NAMs To Treat Stress-Induced Visceral Pain 6/3/2015 7:45:21 AM
Addex Therapeutics (ADXN.SW) And Prof. Pisani Present Dipraglurant Data In Rare Inherited Forms Of Dystonia 5/29/2015 8:58:53 AM
Addex Therapeutics (ADXN.SW) Annual General Meeting Scheduled For 11 June 2015 5/27/2015 10:55:28 AM
Addex Therapeutics (ADXN.SW) Enters Collaboration With Prof. Pisani To Explore The Therapeutic Use Of Dipraglurant In The Treatment Of Rare Inherited Forms Of Dystonia 5/7/2015 8:38:33 AM
Addex Therapeutics (ADXN.SW) Reports 2014 Financial Results 4/30/2015 8:47:35 AM
Addex Therapeutics (ADXN.SW) Raises CHF2.8 million In A Private Placement And Extends Cash Runway Through 2017 3/9/2015 8:58:10 AM
Addex Therapeutics (ADXN.SW) Initiates Dipraglurant Receptor Occupancy Clinical Study In Collaboration With Johns Hopkins University With Funding From The Michael J. Fox Foundation 2/23/2015 10:29:31 AM
Addex Therapeutics (ADXN.SW) mGluR2 NAM Demonstrates Protection In Preclinical Model Of Ischemic Neuronal Death 2/19/2015 11:17:08 AM
12345678910...
//-->